Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.34 USD | +2.60% | +1.88% | -42.59% |
Jun. 03 | PetMed Express, Inc. Announces Executive Changes | CI |
Jun. 03 | PetMed Express, Inc. Announces Christine Chambers Will Leave the Company in Early August 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The stock, which is currently worth 2024 to 0.15 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-42.59% | 88.52M | C | ||
-13.88% | 8.24B | B | ||
+38.40% | 1.33B | - | ||
-12.98% | 346M | - | ||
+0.14% | 267M | - | ||
+10.56% | 227M | - | - | |
-14.68% | 81.59M | - | - | |
+26.03% | 62.4M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PETS Stock
- Ratings PetMed Express, Inc.